SOVALDI 400mg Price

Overview

Welcome to Dwaey, specifically on SOVALDI 400mg Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Sofosbuvir.
SOVALDI 400mg is available in the market in concentration 400mg/Tablet and in the form of Tablets/Film-coated.

GILEAD SCIENCES INTERNATIONAL LTD. is the producer of SOVALDI 400mg and it is imported from UK, The most popular alternatives of SOVALDI 400mg are listed downward .

Mode Of Action

Nucleotide prodrug that undergoes metabolism to the active uridine analog triphosphate, an inhibitor of HCV NS5B RNA-dependent polymerase; its inhibition in turn suppresses viral replication .

Indication

• Chronic Hepatitis C
• Patients with hepatocellular carcinoma awaiting liver transplantation

Precaution

Pregnancy: Ribavirin may cause birth defects and fetal death and animal studies have shown interferons have abortifacient effects; avoid pregnancy in female patients and female partners of male patients. Patients must have a negative pregnancy test prior to initiating therapy, use at least 2 effective methods of contraception and have monthly pregnancy tests. Lactation: Unknown if distributed in human breast milk; take into account the importance of therapy to the mother when administered combination with ribavirin and/or peg-interferon alfa; because of the potential for adverse reaction, breastfeeding is not recommended

Side Effects

• >10% Sofosbuvir plus ribavarin (12 weeks) Fatigue (38%)
• Headache (24%)
• Nausea (22%)
• Insomnia (15%)
• Pruritus (11%)
• Sofosbuvir plus ribavarin (24 weeks)
• Fatigue (30%)
• Headache (30%)
• Nausea (13%)
• Insomnia (16%)
• Pruritus (27%)
• Asthenia (21%)
• Diarrhea (12%) Sofosbuvir plus ribavarin plus peg-interferon (12 weeks) Fatigue (59%)
• Headache (36%)
• Nausea (34%)
• Insomnia (25%)
• Pruritus (17%)
• Anemia (21%)
• Rash (18%)
• Decreased appetite (18%)
• Chills (17%)
• Influenza-like illness (16%)
• Pyrexia (18%)
• Diarrhea (12%)
• Neutropenia (17%)
• Myalgia (14%)
• Irritability (13%) Sofosbuvir plus ribavarin plus peg-interferon (24 weeks) Fatigue (55%)
• Headache (44%)
• Nausea (29%)
• Insomnia (29%)
• Pruritus (17%)
• Anemia (12%)
• Rash (18%)
• Decreased appetite (18%)
• Chills (18%)
• Influenza-like illness (18%)
• Pyrexia (14%)
• Diarrhea (17%)
• Neutropenia (12%)
• Myalgia (16%)
• Irritability (16%) 1-10% Sofosbuvir plus ribavarin (12 weeks) Anemia (10%)
• Asthenia (6%)
• Rash (8%)
• Decreased appetite (6%)
• Chills (2%)
• Influenza-like sickness (3%)
• Pyrexia (4%)
• Diarrhea (9%)
• Myalgia (6%)
• Irritability (10%) Sofosbuvir plus ribavarin (24 weeks) Anemia (6%)
• Rash (9%)
• Decreased appetite (6%)
• Chills (2%)
• Influenza-like sickness (6%)
• Pyrexia (4%)
• Myalgia (9%)
• Irritability (10%) <1% Neutropenia
• Pancytopenia
• Severe depression (particularly in patients with pre-existing psychiatric illness)

Contra indication

When Sofosbivur is used in combination with Ribavirin or Peginterferon alfa/Ribavirin, the contraindications applicable to those agents are applicable to combination therapies. Sofosbuvir combination treatment with Ribavirin or Peginterferon alfa/Ribavirin is contraindicated in women who are pregnant or may become pregnant and men whose female partners are pregnant, because of the risks for birth defects and fetal death associated with Ribavirin.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Pregnancy Category: B; Category X when used in combination with ribavirin or peginterferon alfa/ribavirin